$263,502 awarded Since 1998, the FSH Society has transformed FSHD research by providing grants for vital start-up funding for investigators in FSHD and research projects on FSHD. The milestones and insights gained… Read More »
FSH Society grant awards for February 2015 cycle
Clinical Trial Readiness for Facioscapulohumeral muscular dystrophy
The FSH Society is co-funding the second FSHD Trial Preparedness Workshop. The Workshop, held from May 29-30, 2015, at the University of Rochester Medical Center in Rochester, New York, will convene… Read More »
FSH Society funds genome editing project
Genome Editing, or the ability to make designer changes to the human genome, was once firmly in the realm of science fiction, but recent discoveries have changed that. Although it… Read More »
Facio partners with Evotec and initiates FSHD drug discovery program
From the Facio Therapies website Facio Therapies and Evotec have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression… Read More »
aTyr Receives U.S. FDA Orphan Designation for FSHD drug
San Diego-based aTyr Pharma (“aTyr”), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that Resolaris™ has been granted Orphan Drug Designation… Read More »